GH Trading Analysis - 10/08/2026 12:37 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for GH (Guardant Health) suggests the following relevant themes that may frame the data below:

• GH announced expanded reimbursement coverage for its liquid biopsy tests by a major U.S. payer in early October 2026, a potential long-term catalyst.
• The company is expected to report Q3 2026 earnings in late November 2026, historically a high-volatility event for the stock.
• Biotech sector weakness tied to rising rates and risk-off sentiment pressured speculative names including GH through October.
• An analyst note in September 2026 highlighted accelerating test volume but persistent operating losses, creating mixed sentiment.
• Broad market volatility around the 2026 midterm election season may amplify GH's beta of 1.72.

These headlines provide context only. The data-driven analysis below is strictly based on the embedded GH dataset and does not rely on external news validation.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for GH:

• Trailing EPS is -3.50, confirming the company is not profitable on a trailing basis.
• Trailing P/E, forward P/E, PEG ratio, price-to-book, profit margins, ROE, and debt-to-equity are all null or not provided — valuation via multiples is unavailable.
• Revenue growth, total revenue, and free cash flow are null; no fundamental growth trend can be computed.
• Dividend yield is 0.00 with no dividend rate or ex-dividend date.
• Market cap is $21,852,476,640.00 with 134,196,000 shares outstanding.
• Institutional ownership is 73.81%, indicating strong professional sponsorship.
• 52-week range: low $61.00, high $191.05 (current price well below high).
• Beta is 1.72 (elevated systematic risk); historical volatility is 49.23%.
• Average volume is 1,925,000; analyst target mean and recommendation key are null.

Fundamentals show a loss-making, high-beta micro-to-mid cap biotech with institutional backing but no disclosed profitability or growth metrics. This diverges from the technical picture, where price previously rallied to $191.05 then fell to $162.84, reflecting sentiment-driven movement rather than fundamental support.

Current Market Position

From the embedded data: Daily close on 2026-10-07 was $168.50 (also current_price per indicators). Minute bars show 2026-10-07 opened $166.50, ranged $165.00–$171.55, closed $168.50 on volume 1,622,839. By 2026-10-08 12:10, price declined to $162.84 (open $162.02, high $162.84, low $162.02, volume 12,204). The last 5 minute bars show consistent lower closes: $163.28 → $162.96 → $162.67 → $162.02 → $162.84, indicating intraday bearish drift.

Technical Analysis

Price is below SMA 5 ($176.19) and SMA 20 ($174.59) but above SMA 50 ($167.16), showing short-term weakness within a longer uptrend. No golden/death cross on these lines. RSI 35.82 indicates bearish momentum but not oversold (<30). MACD (2.78) > signal (2.22), histogram positive 0.56 — mild bullish momentum contrary to price drop. Bollinger mid $174.59, price below mid and near lower $160.76 (expansion after 10-06 spike to $191.05). 30-day range: price at $168.50 is 24.5% above low, 11.8% below high. ATR $8.05 implies daily swing risk.

True Sentiment Analysis (Delta 40-60 Options)

From GH_options_20261008_1237.json (Delta 40-60 only, 1.9% filter):

Call Volume: $391,670.00 (13.8%) Put Volume: $2,447,110.00 (86.2%) Total: $2,838,780.00

• Sentiment: Bearish
• Call contracts 323 vs put contracts 1,663 — heavy put dominance.
• Pure directional conviction is bearish; institutions positioning for downside via puts.
• Divergence: MACD mildly bullish, but options flow strongly bearish (noted in spread recommendations).

Key Price Levels (Observational Only)